| Literature DB >> 29535978 |
Winnie-Pui-Pui Liew1, Sabran Mohd-Redzwan1.
Abstract
The secondary metabolites produced by fungi known as mycotoxins, are capable of causing mycotoxicosis (diseases and death) in human and animals. Contamination of feedstuffs as well as food commodities by fungi occurs frequently in a natural manner and is accompanied by the presence of mycotoxins. The occurrence of mycotoxins' contamination is further stimulated by the on-going global warming as reflected in some findings. This review comprehensively discussed the role of mycotoxins (trichothecenes, zearalenone, fumonisins, ochratoxins, and aflatoxins) toward gut health and gut microbiota. Certainly, mycotoxins cause perturbation in the gut, particularly in the intestinal epithelial. Recent insights have generated an entirely new perspective where there is a bi-directional relationship exists between mycotoxins and gut microbiota, thus suggesting that our gut microbiota might be involved in the development of mycotoxicosis. The bacteria-xenobiotic interplay for the host is highlighted in this review article. It is now well established that a healthy gut microbiota is largely responsible for the overall health of the host. Findings revealed that the gut microbiota is capable of eliminating mycotoxin from the host naturally, provided that the host is healthy with a balance gut microbiota. Moreover, mycotoxins have been demonstrated for modulation of gut microbiota composition, and such alteration in gut microbiota can be observed up to species level in some of the studies. Most, if not all, of the reported effects of mycotoxins, are negative in terms of intestinal health, where beneficial bacteria are eliminated accompanied by an increase of the gut pathogen. The interactions between gut microbiota and mycotoxins have a significant role in the development of mycotoxicosis, particularly hepatocellular carcinoma. Such knowledge potentially drives the development of novel and innovative strategies for the prevention and therapy of mycotoxin contamination and mycotoxicosis.Entities:
Keywords: aflatoxin; fumonisin; hepatocellular carcinoma; intestine; mycotoxicosis; ochratoxin; trichothecene; zearalenone
Mesh:
Substances:
Year: 2018 PMID: 29535978 PMCID: PMC5834427 DOI: 10.3389/fcimb.2018.00060
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
In vivo experiments: Gut microbiota alteration by mycotoxins.
| 1 | Male Swedish Landrace x Yorkshire pigs; SPF | Not specified, 20 kg | Post-valve T-caecum cannulas pig treated with 0.05 mg DON/kg BW /day: Before and after exposure to feces from pigs with DON de-epoxidation ability | 5 | Daily for 10 weeks | Terminal restriction fragment length polymorphism (T-RFLP) | No difference could be detected in the T-RFLP profiles in the intestinal microflora between samples from pigs before and after acquiring the ability to de-epoxidate trichothecenes. | The deoxynivalenol de-epoxidation ability was found in fecal and ileal, 1 week after the pigs were exposed to feces from pigs known to have the de-epoxidation ability. | Eriksen et al., |
| 2 | Large White pigs; SPF | 9-week-old | Healthy and DON (2.8 mg/kg) treated rat | 24 | Daily for 4 weeks | Capillary Electrophoresis Single-Stranded Conformation Polymorphism (CE-SSCP) | The species richness index was significantly increased by DON exposure. | A significant reduction of daily weight gain was observed in piglets exposed to the contaminated diet when compared to control. | Waché et al., |
| 3 | Male Sprague-Dawley rats; GF | 8 weeks old, 120–150 g | Germ-free rats inoculated with human fecal: Untreated and treated with DON (100mg/kg BW) | 20 | Daily for 4 weeks | Real-time PCR | DON significantly increased Bacteroides/Prevotella group and decreased concentration levels for | - | Saint-Cyr et al., |
| 4 | Female Wistar rats; Pregnant | Not specified | Healthy pregnant rat fed with normal diet and DON-contaminated diet (10 mg/kg) | 24 | Daily for 4 weeks | 16S sequencing | No difference could be detected in the intestinal microflora between control group and DO-treated group. | DON exacerbates the DNA damage induced by | Payros et al., |
| 5 | Large-White piglets; SPF | 4 weeks old, 41.6 kg | Healthy piglets fed with normal diet and diet containing 12 mg/kg of fumonisins (Mixture of FB1 and FB2) | 48 | Daily for 63 days | Capillary Electropho-resis Single-Stranded Conformation Polymorphism (CE-SSCP) | Fumonisins decreased the fecal microbiota SSCP-profiles similarity between the fumonisins treated and the untreated control group. | Fumonisins affected sphingolipid [sphinganine (Sa) and sphingosine (So)] metabolism. | Burel et al., |
| 6 | Male Fischer 344 rats | 6–7 weeks old | Healthy and OTA (70 and 210 μg/kg BW) treated rat | 18 | 5 days/ week for 4 weeks | 16S rRNA and shotgun sequencing | OTA increased Lactobacillaceae and decreased Bacteroidaceae in relative abundance. In genus level, Bacteroides, Dorea, Escherichia, Oribacterium, Ruminococcus, and Syntrophococcus were decreased and Lactobacillus increased. Facultative anaerobes were increased whereas anaerobes were reduced. | Changes in functional genes of gut microbiota including signal transduction, carbohydrate transport, transposase, amino acid transport system, and mismatch repair were observed. | Guo et al., |
| 7 | Male Fischer 344 rats | 5-weeks old, 120–130 g | Healthy and AFB1 treated rat; control, low (5 mg AFB1/kg BW), medium (25 mg/kg BW), high (75 mg/kg BW) | 20 | 5 days/ week for 4 weeks | 16S sequencing | Fecal: Clostridiales and Bacteroidales were increased in a dose-dependent manner of AFB1. In contrast, Lactobacillales from Firmicutes, Streptococcus sp. and Lactococcus sp. were decreased in a dose-dependent manner of AFB1 exposure. | - | Wang et al., |
| 8 | Male Broiler chicks | 1 day old | Healthy and AFB1 treated rat; control, 2 ppm, 1.5 ppm, 1 ppm daily | 240 | Daily for 21 days | Differential Agar (deMan Rogosa Sharpe for LAB; MacConkey for Gram-negative bacteria | AFB1 significantly reduced total LAB in chickens that received 1 ppm AFB1. In chickens fed with 2 and 1.5 ppm AFB1, the total number of Gram-negative bacteria and LAB were significantly increased. | AFB1 increased the heterophils-to-lymphocyte ratio. The villus length in both duodenum and ileum increased significantly by AFB1 as well as a reduction in duodenum crypt. | Schmeits et al., |
| 9 | Female BALB/c mice | Not specified | Germfree and conventional microflora mice treated with AFB1 (10 mg/kg P.O) or dimethylsulfoxide (control) | 12 | 1 h | CFU counts | Liver: Greater numbers of bacterial mutants were recovered from the conventional flora mice than from the germfree mice after AFB1 treatment. | Potentiated toxic effects. | Rowland, |
| 10 | Gilts | 25 ± 2 kg | Healthy and mycotoxin mixture treated gilts; control, 40 μg ZEA/kg BW + 12 μg DON/kg BW | 75 | Daily for 6 weeks | Differential Agar | ZEA and DON mixture significantly reduced amounts of | Mixture of ZEA and DON increased amino acid metabolism in microbiota. | Piotrowska et al., |
| 11 | Dairy calves | Less than 1 month and mature calf | Mycotoxin [aflatoxin (1–3 ppb) and fumonisin (50–350 ppb)] induced HE calf: Untreated and treated with Celmanax®/Dairyman's Choice™ | From 3 production sites (Not specified) | Daily for 14 days | CFU counts | Fecal: Aflatoxin and fumonisin increased Shiga Toxin-producing | Aflatoxin exposure affects the STEC-secreted cytotoxin composition indicated by increasing intracellular Ca2+ concentrations corresponding to increased cytotoxicity. | Baines et al., |
Figure 1The involvement of gut microbiota in the pathogenesis of HCC. Ingestion of mycotoxin-contaminated foods induces HCC, which eventually leads to the intestinal dysbiosis. The perturbation of microbial balance in the intestine causes a decrease of beneficial gut bacteria. Without the protection from beneficial bacteria, the growth of pathogens will expand rapidly and produce high level of LPS. The presence of LPS exacerbates the condition of HCC. Restoration of gut microbiota balance via intake of probiotics can alleviate the tumorigenic effects in HCC. HCC, hepatocellular carcinoma; LPS, lipopolysaccharide.